Current drug-driving laws create a legal paradox for medical cannabis patients, who face blanket prohibitions despite using prescribed medications at therapeutic doses. This disconnect between medical legitimacy and legal reality affects thousands of patients managing chronic conditions through cannabis-based therapies.
The CAN-TRACK protocol establishes Australia's first controlled comparison of driving impairment between prescribed medical cannabis and the legally accepted 0.05% blood alcohol threshold. The study tracks 72 chronic pain, anxiety, and insomnia patients through real-world driving assessments using standardized doses of their THC-containing prescriptions, measuring lateral vehicle control as the primary safety metric. A parallel phase tests 24 healthy participants under controlled alcohol versus placebo conditions, creating direct comparative data between these two psychoactive substances.
This research addresses a critical evidence gap in drug policy and road safety. Current zero-tolerance THC laws assume all cannabis use produces equivalent impairment, ignoring dosage, tolerance, and medical context. Yet alcohol remains legal at measurable blood concentrations based on established impairment thresholds. The study's semi-naturalistic design using actual patients and prescribed doses offers more realistic impairment data than traditional laboratory studies with recreational users. However, the relatively small sample size and focus on specific medical conditions may limit broader applicability. If therapeutic cannabis doses show minimal driving impairment compared to legal alcohol levels, this could catalyze policy reforms allowing evidence-based THC thresholds rather than absolute prohibitions, potentially removing a major barrier to medical cannabis access.